Cassava Sciences Announces Completion of an Interim Safety R

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials...

Related Keywords

Australia , Texas , United States , Puerto Rico , Canada , South Korea , Eric Schoen , Remi Barbier , Cassava Sciences , Nasdaq , Research International , Cassava Sciences Inc , Safety Monitoring Board , Recently Evaluated , Interim Patient Safety Database , Oral Simufilam , On Going Phase , Both Phase , Clinical Safety Data , Simufilam Are Expected , Cassava Science , Premier Research International , More Information Contact , Chief Financial , Note Regarding Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report ,